
Medline Inc (MDLN) Stock Forecast & Price Target
Medline Inc (MDLN) Analyst Ratings
Bulls say
Medline Inc's Supply Chain Solutions segment generated $13 billion in revenue for fiscal year 2024, reflecting a 12% increase year-over-year, with organic growth of 9.5%, indicating robust market demand. The company's overall revenue growth remains strong, with Medline Brand contributing $12.5 billion in revenue, up 7.8% year-over-year, alongside an impressive adjusted EBITDA of $3.4 billion for Medline Brand, which marked a 21% increase from the previous year and resulted in a corporate-wide EBITDA margin of 13.2%. Historically resilient during economic downturns, Medline has demonstrated the ability to grow revenues significantly, as evidenced by a 17% compound annual growth rate during the 2008-2009 financial crisis and an 11% CAGR during the COVID pandemic, highlighting the enduring demand for medical supplies and solutions amidst changing healthcare needs.
Bears say
The analysis highlights several fundamental reasons for a negative outlook on Medline Inc.'s stock. Healthcare providers are currently contending with low margins exacerbated by inflation, staffing shortages, and policy shifts, which may impact Medline's sales as hospitals anticipate reduced patient volumes and tighter budgets. Additionally, Medline's significant debt load could hinder its ability to pursue mergers and acquisitions, further constraining its growth potential in an already competitive and consolidated market where losing key customers poses a significant risk to revenue and earnings stability.
This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.
Medline Inc (MDLN) Analyst Forecast & Price Prediction
Start investing in Medline Inc (MDLN)
Order type
Buy in
Order amount
Est. shares
0 shares